Viking Therapeutics, Inc.
$29.33
+0.037%Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -9.2).
Valuation inputs: P/E -9.2, earnings yield N/A, momentum +0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -56.3%, ROIC -61.5%).
Profitability stack: net margin 0.0%, ROE -56.3%, ROIC -61.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +10.7%, momentum +0.0%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Viking Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Viking Therapeutics, Inc. Fair Value Envelope
No Revenue Data
VKTX has not reported any revenue values in the available annual periods.
Viking Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
VKTX has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
VKTX has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
VKTX has not reported any net profit margin values in the available annual periods.
Viking Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Viking Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Viking Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that VKTX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 93.60, with estimates ranging from a low of 83.00 to a high of 101.00.
The consensus 1-year price target stands at 93.60, with estimates ranging from a low of 83.00 to a high of 101.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Viking Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $150K and sold $5.95M worth of VKTX shares, resulting in $5.80M of net selling activity.
3 Months
4.5K
149.91K
0
0.00
+150K
+$150K
3-6 Months
0
0.00
32.0K
1.03M
-1.0M
-$1.03M
6-9 Months
0
0.00
111.4K
3.93M
-3.9M
-$3.93M
9-12 Months
0
0.00
35.4K
984.53K
-985K
-$985K
Top Buyers
Aubuchon Neil William
Officer: Chief Commercial Officer
$150K
Top Sellers
Rowland Charles A Jr
Director
$2.13M
Lian Brian
Director, Officer: President & Ceo
$2.11M
Zante Greg
Officer: Chief Financial Officer
$1.37M
Mancini Marianna
Officer: Chief Operating Officer
$335K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $5.80M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
4 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
VKTX has not reported any dividend yield values in the available annual periods.
vktx Dividend History
Learning Layer
Related Guides
Build conviction on VKTX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.